Objective-Obstructive thrombi or thrombotic emboli are the pathogenic basis of ischemic stroke. In vitro blood clots and in vivo thrombi can undergo platelet-driven contraction (retraction), resulting in volume shrinkage. Clot contraction can potentially reduce vessel occlusion and improve blood flow past emboli or thrombi. The aim of this work was to examine a potential pathogenic role of clot contraction in ischemic stroke. Approach and Results-We used a novel automated method that enabled us to quantify time of initiation and extent and rate of clot contraction in vitro. The main finding is that clot contraction from the blood of stroke patients was reduced compared with healthy subjects. Reduced clot contraction correlated with a lower platelet count and their dysfunction, higher levels of fibrinogen and hematocrit, leukocytosis, and other changes in blood composition that may affect platelet function and properties of blood clots. Platelets from stroke patents were spontaneously activated and displayed reduced responsiveness to additional stimulation. Clinical correlations with respect to severity and stroke pathogenesis suggest that the impaired clot contraction has the potential to be a pathogenic factor in ischemic stroke. 
S
troke is a leading cause of death and disability worldwide 1,2 and accounts for 1 in every 20 deaths in the United States each year. 3, 4 Despite this clinical importance and numerous studies on circulatory disorders in the brain vessels, the pathogenesis of stroke remains largely unclear, and the results of stroke prophylaxis and treatment are unsatisfactory. 5 Brain damage caused by abnormalities of cerebral blood flow is often ischemic by nature 2 and is associated with thrombosis or thromboembolism, indicating involvement of hemostatic reactions. 6, 7 Hypercoagulability and changes in blood rheology in combination with local dysfunction and destruction of endothelium comprise a pathogenic basis for ischemic stroke. 6, [8] [9] [10] In addition to disorders of plasma and vascular hemostasis, platelet activation plays a role in ischemic stroke. 6, 10, 11 Platelet stimulation and aggregation are followed by release of potent triggers of the coagulation cascade and secondary platelet activation.
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A main physiological activator of platelets is thrombin, an enzyme that forms in the blood irrespective of the initial cause of intravascular blood clotting. Concomitant with platelet activation, thrombin converts fibrinogen, a soluble plasma protein, into an insoluble fibrin gel made of a filamentous network. [12] [13] [14] Fibrin sticks to activated platelets via the integrin receptor αIIbβ3 to form a platelet-fibrin meshwork comprising the structural basis of a hemostatic clot or an obstructive thrombus. 12, 15, 16 When the blood clot is formed in a tube, it undergoes volume shrinkage, and liquid serum is expelled. This process is called clot contraction or retraction. 17 The cellular and molecular composition of the blood clot has been found to influence the rate and extent of clot contraction. 18 Importantly, contraction occurs not only in vitro but also inside a vessel if a clot or thrombus is formed. 19 The importance of clot contraction in vivo is based on at least 2 mechanisms: (1) at the site of tissue injury, the active decrease in clot size reduces blood loss by pulling together wound edges and (3) blood flow is recovered past a contracted formerly obstructive thrombus, the latter being hypothetically an important compensatory or adaptive mechanism in thrombotic states. 17, 19, 20 Despite potential medical significance, clot contraction has not been studied systematically in clinical settings mainly because of no standardized and automated methods for registration and quantification of this process. Previously, a limited number of studies assessed extent of clot contraction in vitro subjectively as a visible ratio of the volume of serum and the reduced volume of the clot. It is not surprising that the parameters of clot contraction under various circumstances are hardly comparable and highly scattered with the normal range of the extent of contraction varying from 20% to 90%. In this work, we use a recently described instrumental technique 18 that enabled us to quantify the kinetics of blood clot contraction in normal and disease states.
The goal of this work was to evaluate the potential pathogenic importance of clot contraction in acute ischemic stroke by correlating the parameters of clot contraction with clinical and laboratory characteristics.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Comparison of Hemostatic and Hematologic Profiles in Stroke Patients and Healthy Donors
Hemostatic and hematologic parameters for stroke patients and healthy donors are shown in Table 1 . Comparison of these parameters revealed an elevation in fibrinogen and D-dimer levels and a decrease in the rate of ADP-induced platelet aggregation in stroke patients (Table 1 ). In addition, stroke patients had a reduced platelet count and increased fibrinogen level, hematocrit, erythrocyte sedimentation rate, and leukocyte count. In vitro model experiments with variation of the platelet count and fibrinogen levels suggest that clot contraction can be directly modulated by these blood constituents. In particular, clot contraction was enhanced by the increasing number of platelets ( Figure IIA in the online-only Data Supplement), whereas fibrinogen had a dose-dependent inhibitory effect ( Figure IIB in the online-only Data Supplement), consistent with the changes in blood composition observed in the stroke patients. Because the molecular and cellular composition of the blood impacts the process of clot contraction, 18 these differences collectively suggest that clot contraction has the potential to differ in healthy donors and stroke patients.
Characterization of Clot Contraction in Stroke Patients
Automated optical tracking of clot size ( Figure 1A and 1B) revealed a 60% reduction in the average extent of clot contraction at the end point in stroke patients relative to healthy donors ( Figure 1C ), which resulted in stroke patients having a significantly larger clot size. Stroke patients also had a reduced average velocity and area over the curve while having a prolonged lag time ( Figure 1D and 1E) . Cross-correlation of clot contraction parameters revealed that extent of clot contraction, average velocity, and area over the curve were all strongly correlated with each other, suggesting a mechanistic relationship between the parameters. Interestingly, although lag time and extent of clot contraction were not significantly correlated in healthy donors, there was a significant negative correlation between these 2 parameters in stroke patients, suggesting that reduced platelet activity increases the lag time and decreases the extent of clot contraction (Tables I and II in samples from patients with TIA were analyzed. It was found that TIA patients also had a significantly reduced extent of contraction, average velocity, lag time, and area over the curve (P<0.01 for average velocity, P<0.0001 for all other parameters), whereas clot contraction in TIA patients did not significantly differ from that of ischemic stroke patients (Table III in the online-only Data Supplement).
Kinetic Phase Analysis of Clot Contraction in Stroke Patients
It has been shown previously that clot contraction in the blood of healthy subjects occurs in 3 phases: initiation of contraction (phase 1), linear contraction (phase 2), and mechanical stabilization (phase 3). 18 Regression analysis conducted on average kinetics curves ( Figure 2 ) revealed that stoke patients and healthy donors did not have a difference in the duration of the different phases or in the rate constant associated with phase 1 (Table 2) . However, the rate constants of the linear phase 2 and the exponential phase 3 were significantly reduced by 2 times and 10 times, respectively, in stroke patients compared with healthy subjects, indicating impairment of the mechanisms of compaction (phase 2) and stabilization of the clots (phase 3).
Correlation Between Contraction Parameters and Laboratory Tests
Because the observed differences between clot contraction in healthy subjects and stroke patients were likely related to disorders of hemostasis and changed blood composition, we investigated correlations between the extent of clot contraction and hemostatic, hematologic, and biochemical parameters (Table IV in the online-only Data Supplement). The main finding was that the extent of clot contraction moderately but significantly correlated with the platelet count in stroke patients. We also revealed slight but significant correlations between the extent of clot contraction and prothrombin time (prothrombin index and international normalized ratio) and hematocrit in healthy subjects, whereas these correlations were not present in stroke patients. In stroke patients, only monocyte count weakly but significantly correlated with the extent of clot contraction (r 2 =0.2839; P<0.001).
Analysis of Platelet Function and Morphology in Stroke Patients
Because platelets are critical for the contractile force generated during clot retraction, we studied the functionality of platelets in ischemic stroke using flow cytometry-based evaluation of the baseline activity of quiescent platelets and their responsiveness to chemical activation. We used thrombin receptoractivating peptide (TRAP) to mimic the effect of thrombin on protease-activated receptors without a risk of fibrin formation that would complicate the assay. Platelet reactivity was assessed by surface expression of P-selectin and by the ability to bind fibrinogen as a measure of the integrin αIIbβ3 activation. In addition, isolated unstimulated platelets from ischemic stroke patients were studied with scanning electron microscopy to assess their functional status reflected by their shape. In stroke, platelets were initially activated as revealed by a higher Optical tracking system used for measurements of clot contraction. A, The optical analyzer (side view) used to measure light scattering during the process of clot contraction. B, The changes in relative clot size are converted into a kinetic curve that can be analyzed for (a) the extent of clot contraction at 20 min, (b) the lag time or the time to 5% contraction, and (c) the area over the curve (AOC) that characterizes the entire process of clot contraction and integrates the extent and rate of contraction and the lag time. Optical tracking was used to assess differences in between healthy subjects and stroke patients in (C) extent of clot contraction, (D) average velocity of contraction, (E) AOC, and (F) lag time. Parameters for healthy subjects and stroke patients were compared using an unpaired, 2-tailed Student t test. ****P<0.0001. level of P-selectin expression in unstimulated cells (Table 3 ; Figure III in the online-only Data Supplement). This observation was confirmed by the frequently observed shape change and formation of filopodia in platelets from stroke patients (34%) compared with morphologically altered platelets from healthy subjects (9%, P<0.0001; Figure IV in the online-only Data Supplement). In response to TRAP-induced stimulation, platelets from the blood of ischemic stroke patients had a significantly lower expression of P-selectin compared with TRAP-activated normal platelets. TRAP-induced stimulation also resulted in reduced fibrinogen-binding capacity compared with the TRAP-activated normal platelets. Collectively, these results indicate that in ischemic stroke, platelets are initially partially activated and have a reduced responsiveness to a thrombin-like stimulus. It is noteworthy that the ratio of activated versus quiescent cells for both fluorescent markers was ≈2-to 4-fold higher in healthy donors compared with stroke patients, suggesting, in combination with the reduced exposure of P-selectin and fibrinogen-binding activity, that the stroke platelets have a substantially decreased overall activation potential. As a matter of fact, contraction in the group of stroke patients studied for platelet functionality was significantly impaired with an average extent of 28±7% versus 51±1% for control (P<0.0001).
Analysis of Clot Contraction Based on the Severity of Stroke
The National Institutes of Health Stroke Scale (NIHSS) is a validated clinical methodology to assess the severity of stroke in scale from 0 to 42, where <15 corresponds to a minor-tomoderate stroke and >15 corresponds to a moderate-to-severe or severe stroke. Modified Rankin scale measures rank the level of disability after stroke with 0 representing no symptoms and 5 representing severe disability. 21 The Alberta Stroke
Program Early CT score value is inversely related to the area of damage as determined through a topographical evaluation of damage. 22 Within the cohort of patients in this study, the NIHSS value correlated strongly with modified Rankin scale score and inversely with Alberta Stroke Program Early CT score (Table V in the online-only Data Supplement).
The stroke patient population was divided based on NIHSS value to compare those with a value <15 to those with a value >15. We found that patients with more severe strokes (NIHSS >15) had a moderately but significantly increased extent of clot contraction, average velocity, area over the curve, and a reduced lag time when compared with patients with minor and moderate stroke (NIHSS <15; Figure 3 ). It is noteworthy that regardless of stroke severity the patients had a significantly reduced extent of clot contraction compared with healthy subjects, and neither subgroup of stroke patients differed significantly from the total stroke patient population (Tables VI and  VII in the online-only Data Supplement). Hemostatic, hematologic, and biochemical parameters were compared for the populations of stroke patients divided based on NIHSS score (Table VII in the online-only Data Supplement). Patients with an NIHSS score >15 had a faster activated partial thromboplastin time and increased fibrinogen level, D-dimer level, platelet count, leukocyte count, and protein S-100 level.
Analysis of Clot Contraction Based on Pathogenesis of Stroke
To reveal whether the notable alterations in clot contraction in stroke patients had a pathogenesis-related significance, we investigated differences between subpopulations of stroke patients as defined by the TOAST classification (Trial of Org 10172 in Acute Stroke Treatment; Table 4 ), which allows for a distinction to be made between the following pathogeneses of ischemic stroke: (1) large-vessel atherosclerosis, (2) cardioembolism, 3) small-vessel occlusion, (4) stroke of other determined pathogenesis, and (5) stroke of undetermined pathogenesis. 23 Because of the small number of patients with TOAST subtypes 3 to 5, we preceded with analysis of clot contraction in patients with cardioembolic and atherothrombotic strokes. Assessment of extent of clot contraction based on stroke subtype revealed that there was a lower extent of clot contraction in patients with cardioembolic strokes when compared with patients with atherothrombotic strokes (Figure 4) . 
Discussion
Stroke is a leading cause of death and disability worldwide. 4 Although the pathogenesis of ischemic stroke is complex and heterogeneous, a common link between the different pathogeneses is increased activity of the coagulation and fibrinolytic systems 10 in conjunction with macro-and microvessel disruption 9 manifesting in thrombotic events. A thrombus or thrombotic embolus can result in blockage of blood flow to a portion of the brain; size and location of the thrombotic event influences stroke severity and functional outcome. 24 Brain tissue is a prominent source of tissue factor (TF), 25 and locations of brain damage are associated with high levels of TF and other procoagulant compounds, 26 which can intensify hypercoagulability and potentially lead to exhaustion of anticoagulant mechanisms and functional impairment of platelets. 27 Information gleaned from in vitro and ex vivo studies of clot structure has been widely used to inform clinical findings. 28 Thrombi collected from ischemic stroke patients have a platelet-fibrin network interspersed with cells, and those rich in red blood cells (RBCs) are generally more susceptible to thrombolysis. 29 In ischemic stroke, the structure of thrombi is nonhomogenous, but, on average, RBCs comprise 34% of the volume, 30 which can influence the process of clot contraction. 18 Interestingly, fibrin clots formed in the blood from ischemic stroke patients had abnormal fibrin ultrastructure that could influence contraction of the fibrin-platelet network. 28 Collectively, this provides the need for an examination of clot contraction in samples collected from patients with ischemic stroke.
Blood clot contraction remains the least studied stage of blood clotting. This work is the first systematic assessment of clot contraction in ischemic stroke. The main finding of this work is that clots formed from the blood of patients with ischemic stroke have a reduced extent of clot contraction when compared with clots formed from the blood of healthy subjects (Figure 1 ). This result is somewhat unexpected as ischemic stroke is associated with a procoagulant activity, 9 but the aggregate of laboratory values collected from this cohort of ischemic stroke patients sheds some light on potential mechanisms for impaired clot contraction.
Platelets contain actomyosin machinery that generates contractile forces [31] [32] [33] Number of patients, n (%) 33 (39) 45 (54) 6 (7) 84 (100) Male sex, n (%) 13 (39) 25 (56) 3 (50) 41 (48) Age, y 69±2 68±1 60±4 68±1
Ischemic stroke classifications NIHSS score at the time of admission (median; 1st, 3rd quartile) 9; 4.5, 17 7; 3, 13 4; 3.5, 6 7; 4; 13.5 mRs score (median; 1st, 3rd quartile) 3; 2, 4. platelet-fibrin interactions. 34, 35 Therefore, reduced contraction in stroke patients is likely because of reduced number and functionality of platelets (Table 1) . We confirmed the mechanistic importance of the quantitative and qualitative changes in platelets for clot contraction through in vitro experiments with varying platelet counts ( Figure IIA in the online-only Data Supplement) and through flow cytometry (Table 3 ; Figure III in the online-only Data Supplement) and scanning electron microscopy ( Figure IV in the online-only Data Supplement) of platelets from stroke patients. On the basis of the surface expression of P-selectin, fibrinogen-binding capacity, and morphology, it has been found that platelets in the blood of stroke patients are initially activated and, more importantly, have a dramatically reduced capacity to respond to a thrombin-like activating stimulus. This is consistent with an earlier report that states that platelets from ischemic stroke patients are insensitive to thrombin in vitro, 27 which may result from cleavage of protease-activated receptors, metabolic exhaustion, or other mechanisms. Although a reduced platelet count in stroke is moderate (Table 1) and can have a relatively minor contribution to impaired clot contraction, it is platelet dysfunction that is likely to be the major pathogenic mechanism for reduced clot contraction observed in the blood of stroke patients. Disruption in both platelet number and function results in partial contractile inefficiency.
The prolonged lag phase observed in ischemic stroke (Figure 1 ) could be, in part, because of increase of antithrombin III activity after activation of the clotting cascade (Table 1) , which inhibits thrombin and other clotting factors, 36 resulting in the slightly prolonged activated partial thromboplastin time observed in stroke patients (Table 1) . Reduced thrombin activity strongly correlates with impaired clot contraction and could be a factor here despite addition of exogenous thrombin to initiate clotting. 18 Increased fibrinogen level that can accompany ischemic stroke 37 (Table 1) can suppress clot contraction, which was confirmed in the in vitro experiments ( Figure IIB in the online-only Data Supplement). Higher fibrinogen concentration results in increased fibrin mass and more fibers not associated with activated platelets/platelet aggregates, which can impede clot contraction. 12, 18 In stroke patients, fibrin and RBCs can undergo oxidative and proteolytic changes that result in the formation of densely matted deposits of fibrin and RBCs, which have been implicated to play a role in persistent thrombi. 38, 39 The abnormal fibrin structure associated with ischemic stroke [40] [41] [42] results in lower clot permeability and a slower rate of lysis. 42 Contractile forces that are generated by platelets are able to compress RBCs tightly into the core of clots. 19 Compacted RBCs form a tessellated network and acquire a polyhedral shape, resulting in the terminology polyhedrocytes. 19 Polyhedrocytes have been found inside coronary thrombi extracted from patients with myocardial infarction, 43 confirming that intravascular clots undergo contraction. Increased hematocrit results in a reduced extent and rate of clot contraction, 18 and the higher hematocrit in stroke patients (Tables 1  and 2 ; Figure 2 ) is consistent with this inhibitory effect and could be additional mechanism of impaired contraction in stroke patients.
Based on this data analysis, we propose that collectively the reduced platelet count, increased hematocrit, and increased fibrinogen contribute to the impaired mechanism of clot contraction, which results in vessel occlusion and brain infarct. The compromised contraction of an intravascular clot or thrombus may play an important role in the pathogenesis of ischemic stroke. Although severity of stroke and infarct size are largely determined by the diameter and location of the occluded vessel, the ability of the thrombi to contract either more or less can aggravate or alleviate the course of ischemic brain damage. For example, if clot or thrombus contraction results in a 50% reduction in the vessel cross-sectional area, this would translate to a reduction of blood flow to 24% of that with no clot, whereas the impaired contraction seen in the stroke patients, resulting in an 80% reduction in the vessel cross-sectional area, would reduce the flow rate to 4% of the original.
Interestingly, clot contraction is also reduced in TIA similar to the reduction seen in ischemic stroke patients (Table  III in the online-only Data Supplement), indicating that clot contraction is impaired in these patients. TIA is characterized as a focal neurological deficit that lasts <24 hours and, although ischemic in nature, does not result in infarction. 44 Patients with a recent TIA are at a high risk for the occurrence of an ischemic stroke, 45, 46 and 15% of ischemic stroke patients presented with a previous TIA. 47 Our findings suggest that a premorbid status and predisposition to thrombosis, such as are seen in TIA and ischemic stroke, are critical determinants for the ability of clots to contract rather than a transitory episode of cerebral vascular occlusion and ischemia that may or may not result in persistent thrombosis or thromboembolism. Although rapid treatment of TIA has the potential to help reduce the incidence of ischemic stroke, 48, 49 the TIA samples in our study were examined before the administration of any anticoagulant, thrombolytic, or antiplatelet drugs.
Our results show that despite an overall impairment of contraction in stroke patients, severe strokes had a relative increase in the extent of clot contraction compared with minor/moderate stroke (Figure 4) . NIHSS score >15 also had a higher Protein S-100 level, a molecular marker of brain damage, which is correlated with infarct volume, functional outcome, and ongoing ischemia. 50 We propose that in some cases of stroke with focal brain damage, the contractile activity of clots and thrombi can be improved as a potential compensatory mechanism to decrease the consequences of thrombosis and restore blood flow. In patients with severe ischemic brain damage, the blood-brain barrier is disrupted, 51 and massive amounts of TF are released into systemic circulation, resulting in activation of the extrinsic pathway of blood coagulation. [52] [53] [54] It has been shown that the level of brain damage is associated with the amount of TF that is released. 55, 56 Also, ischemic stroke patients have increased TF-bearing microparticles 57 and TF expression on monocytes. 58 We hypothesize that increased TF could potentially cause a secondary wave of thrombin generation, resulting in a faster activated partial thromboplastin time (Table VI in the online-only Data Supplement) and higher fibrinogen turnover in severe stroke patients. 59 Thrombin can induce highly active platelets in severe ischemic stroke patients, which can be determined through expression of P-selectin. 60, 61 Platelet hyperactivity in combination with increased platelet count (Table VI in the online-only Data Supplement) could explain the increased extent of contraction in patients with more severe stroke compared with less severe stroke ( Figure 3 ).
We propose a dual role of clot contraction in the ischemic stroke (Graphical Abstract in the online-only Data Supplement). Impaired clot contraction results because of changes in blood composition. This impaired clot contraction has the potential to be a pathogenic factor that aggravates the course of disease by increased blockage of blood flow. Enhanced clot contraction occurs in atherothrombotic patients compared with cardioembolic patients (Figure 4) . This supports the idea that TF can potentially enhance contraction in subpopulations of stroke patients because atherothrombotic stroke patients have increased TF 62 and D-dimer, creating a thrombogenic state, 63 and increased P-selectin expression on platelets, indicative of hyperactivity. 64, 65 Cardioembolic strokes are not a result of platelet hyperfunction but rather arise because of blood stasis. 66 This in conjunction with marginally enhanced clot contraction in severe strokes supports the notion that an increased thrombogenic state may result in the enhanced contraction observed here. This enhanced clot contraction has the potential to act as a compensatory or adaptive factor in ischemic stroke. However, this potential requires further examination.
In summary, the pathophysiological significance of clot contraction in thrombotic states has been explored. Clot contraction is associated with the restoration of blood flow past otherwise obstructive thrombi, potentially influencing the outcome of thrombosis. 17, 19, 20 However, compressed, dense thrombi are more impermeable and may be resistant to fibrinolysis. Consequently, clinical consequences of clot contraction in vivo may be ambiguous, resulting in either aggravation or relief of the thrombotic state. Our results reveal that further systematic studies of the clinical importance of clot contraction are worthwhile, as they could inform a novel pathogenic mechanism and result in potential laboratory tests that improve diagnosis of and prognosis in thrombotic conditions such as ischemic stroke.
